Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Publication date: Jul 03, 2019

This phase I trial studies the best dose of sonidegib when given together with pembrolizumab and to see how well they work in treating patients with solid tumor that has spread to other places in the body (advanced). Sonidegib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving sonidegib and pembrolizumab may work better than standard treatment in treating patients with advanced solid tumors.

Concepts Keywords
Adenocarcinoma NSCLC
Adrenal Metastatic tumors
Adverse Event Ability tumor
Alanine Aminotransferase Growth tumor
ALK Urothelial carcinoma
ALT L1 tumor
Amyotrophic Lateral Sclerosis Tumor
ANC Rhabdomyolysis
Aspartate Transaminase Active autoimmune diseases
AST Cancer
Autoimmune Disease Clinical medicine
Autoimmune Diseases Major surgery
Bilirubin Vasectomy
Blood Immunotherapy
BRAF Contraception
Brain Imaging Chemotherapy
Cancer Amyotrophic lateral sclerosis
Capsules Available colorectal cancer
Carcinoma Corticosteroid brain metastases
Central Nervous System Solid tumor
Chemotherapy Solid Tumors
Cisplatin Condition active infection
Cohort MRI
Colorectal Cancer Chemotherapy
Common Tomography
Computed Tomography Antibodies
Concurrent Brain metastasis
Condoms Targeted therapy
Contraception Microsatellite instability
Cooperative Group Antineoplastic drugs
Corticosteroid Pembrolizumab
Corticosteroids Checkpoint inhibitor
Creatinine Non-small-cell lung carcinoma
Creatinine Clearance Sonidegib
CT Scan
CYP3A4
Cytokines
EGFR
FDA
Formula
Gastroesophageal Junction
Gastrointestinal
Genotoxic
Grapefruit
Grapefruit Juice
Hemoglobin
Immune System Attack
Immunohistochemistry
Immunosuppressive Agents
Immunosuppressive Medications
Immunotherapy
Infection
Informed Consent
Intravenously
Irinotecan
Lipids
Liver
Lung
Magnetic Resonance Imaging
Maximum Tolerated Dose
Mayo Clinic
Melanoma
Metastases
Metastatic
Mismatch Repair
Monoclonal Antibodies
Morbidity
MRI
MSI
Muscular Dystrophy
Mutagenic
Myopathies
NCI
Neoplastic
Oxaliplatin
Pancreas
Platelet Count
Platinum
Prednisone
Preexisting Condition
Pregnancy Test
Randomization
Rhabdomyolysis
Serum
Solid Tumor
Spinal Muscular Atrophy
Squamous
Starfruit
Statins
Steroid
Steroids
Swallow
Systemic Therapy
Targeted Therapies
Teratogenic
Tolerability
Topical
Toxicity
Tumor
Vaccine
Vasectomy

Semantics

Type Source Name
drug DRUGBANK L-Alanine
gene UNIPROT TLE5
drug DRUGBANK Tropicamide
disease DOID cancer
pathway BSID Immune System
disease MESH growth
gene UNIPROT MAP6
disease MESH Tumors
gene UNIPROT BEST1
drug DRUGBANK Pembrolizumab
drug DRUGBANK Sonidegib
drug DRUGBANK Creatinine
gene UNIPROT SLC17A5
disease DOID NSCLC
disease MESH non-small cell lung cancer
pathway BSID Non-small cell lung cancer
gene UNIPROT CD274
disease MESH Disease progression
drug DRUGBANK Platinum
gene UNIPROT RPL17
gene UNIPROT PDCD1
gene UNIPROT EGFR
gene UNIPROT ALK
gene UNIPROT BRAF
disease MESH abnormalities
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
disease MESH squamous cell cancer
disease DOID squamous cell cancer
disease MESH carcinoma
disease DOID carcinoma
drug DRUGBANK Cisplatin
disease MESH Microsatellite instability
pathway BSID Mismatch repair
pathway BSID Mismatch Repair
disease MESH colorectal cancer
disease DOID colorectal cancer
pathway BSID Colorectal cancer
drug DRUGBANK Oxaliplatin
drug DRUGBANK Irinotecan
disease DOID gastroesophageal junction adenocarcinoma
disease DOID pancreatic adenocarcinoma
disease MESH inflammatory myopathies
disease MESH muscular dystrophy
disease DOID muscular dystrophy
disease MESH amyotrophic lateral sclerosis
disease DOID amyotrophic lateral sclerosis
disease MESH spinal muscular atrophy
disease DOID spinal muscular atrophy
disease MESH rhabdomyolysis
drug DRUGBANK Pravastatin
gene UNIPROT CYP3A4
disease MESH autoimmune diseases
gene UNIPROT EHD1
drug DRUGBANK Prednisone
disease DOID autoimmune disease
disease MESH metastases
gene UNIPROT CYREN
disease MESH infection
gene UNIPROT NR4A2
gene UNIPROT ALG3

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *